Table S1.

Clinicopathological features and IFI27 expression in patients with CCA

	IFI27 low expression	IFI27 high expression	P
Age (years)	59.50±11.2	61.26±12.6
Gender			0.092
Male	25 (47.2%)	13 (30.2%)
Female	28 (52.8%)	30 (69.8%)
Symptom			0.022*
No	13 (24.5%)	3 (7.0%)
Yes	40 (75.5%)	40 (93.0%)
AST (IU/L)			0.127
≤34	24 (47.1%)	27 (62.8%)
>34	27 (52.9%)	16 (37.2%)
ALT (U/L)			0.625
≤36	28 (58.3%)	26 (63.4%)
>36	20 (41.7%)	15 (36.6%)
ALP (U/L)			0.085
≤94	23 (47.9%)	13 (30.2%)
>94	25 (52.1%)	30 (69.8%)
Bilirubin (total) (mg/dL)			0.187
≤1.3	43 (81.1%)	39 (90.7%)
>1.3	10 (18.9%)	4 (9.3%)
Albumin (g/dL)			0.451
≤3.5	11 (22.9%)	12 (30.0%)
>3.5	37 (77.1%)	28 (70.0%)
Serum CEA (ng/mL)			0.487
≤5	21 (55.3%)	16 (47.1%)
>5	17 (44.7%)	18 (52.9%)
Size (cm)			0.004*
≤5	29 (58.0%)	12 (27.9%)
>5	21 (42.0%)	31 (72.1%)
Lymph node			0.273
Negative	38 (71.7%)	25 (61.0%)
Positive	15 (28.3%)	16 (39.0%)
Differentiated			0.463
Well	1 (1.9%)	2 (4.7%)
Moderate	30 (56.6%)	18 (41.9%)
Poorly	21 (39.6%)	22 (51.2%)
Other	1 (1.9%)	1 (2.3%)
Margin			0.190
Negative	42 (79.2%)	29 (67.4%)
Positive	11 (20.8%)	14 (32.6%)
Post-chemotherapy			0.305
Without	29 (54.7%)	19 (44.2%)
With	24 (45.3%)	24 (55.8%)
Post-radiotherapy			0.816
With	46 (86.8%)	38 (88.4%)
Without	7 (13.2%)	5 (11.6%)

Note:

^*Statistically significant by multi-logistic regression analysis: P=0.048 for symptoms with relative risk (95% CI: 4 [1.01–16.67]); P=0.010 for tumor size >5 cm with relative risk (95% CI: 3.24 [1.33–7.91]).

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCA, cholangiocarcinoma; CEA, carcinoembryonic antigen; IFI27, interferon α-inducible protein 27; IU, international unit.